Synaffix Announces License Agreement with Mersana Therapeutics
Synaffix announced it has entered into a license agreement with Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering...
Read more
Chemist Freek van Cauter: ‘We make molecules here’
At NTRC, chemists and biologists work closely together to develop new drugs, particularly against cancer and Parkinson's disease. Chemist Freek van Cauter gives us a look behind the scenes.
Read more
A cup of coffee with … Roxana Nicolae
This is Roxana Nicolae, originally from Romania and now working for BioConnection at Pivot Park.
Read more
Welcome Absano, Sublin and Agidens
Three new companies Absano, Sublin and Agidens have signed a contract with Pivot Park. Absano is a spin-off company of Modiquest. Sublin is a spin-off company of Nanoserve. Agidens contribute to the safety of the consumer and patient thanks to their experience in automation and in Life Sciences.
Read more
The road to funding
The Funding Event took place at Pivot Park. Start-ups and scale-ups had the opportunity to talk to invited investors.
Read more
Press release: NTRC launches the first HTS Assay for Arginase-1 inhibitors at ENA2018 Copy
NTRC launches the first High-throughput Screening Assay for Arginase-1 inhibitors at ENA2018. Arginase-1 (Arg-1) is an important drug target for cancer immunotherapy.
Read more
Get this presentation about uHTS Copy
SLAS (Society for Laboratory Automation and Screening) visited Europe and the Pivot Park Screening Centre in June this year. During...
Read more
New predictive drug response biomarkers for approved kinase inhibitors
Press release, Oss, November, 02, 2018 Kinase inhibitors illustrate the successful translation of basic scientific knowledge of cancer into new...
Read more